UPMC Physician Resources
- The liver transplant program is one of the oldest and largest in the United States
- More than 7,000 adults have received liver transplants since the program’s inception
- Expertise in solid-organ, living-donor, and multivisceral transplantation
- National leader in treatment and transplant for primary liver cancers
- Pioneered minimally invasive (laparoscopic) liver resection — more than 300 cases performed
Liver Transplantation at UPMC
Liver Transplantation at UPMC is one of the oldest and largest programs in the United States. Throughout our rich history, we have collaborated with referring physicians to develop the best possible courses of treatment for patients with end-stage liver disease.
From the early years when Dr. Starzl pioneered a new field of surgery, to the development of the latest immunosuppressive therapies, these advances have given hope to thousands of patients with liver disease. To ensure optimal continuity of patient care, the UPMC Liver Transplant team pursues a collaborative approach with referring physicians and will partner with you through all stages of your patient's treatment.
Because of our role as a leader in the field of solid organ transplantation, our program is consistently challenged with some of the most difficult and complex cases. Our kidney, liver, intestinal, and pancreas specialists are experts in their fields. Many are involved in leading research into hereditary aspects of disease, novel therapies, and new ways to use antirejection medicines to improve outcomes for patients.
Volumes and Outcomes
Many factors influence a transplant center’s survival rates, including the patient’s condition. Despite a history of caring for patients with complex medical and surgical problems, we maintain outcomes that are at or near national benchmarks. To view specific information about our outcomes, including one- and three-year survival rates, please visit the Scientific Registry of Transplant Recipients.
Research in Abdominal Transplantation
UPMC is a leader in immunosuppressive therapy and other cutting-edge research and advancements. Our latest work focuses on reducing or even, in a few cases, eliminating the need for antirejection medication to support long-term outcomes. This includes pioneering recipient pretreatment (preconditioning) to prevent initial rejection, while reducing the need for high doses of antirejection medications with long-term follow-up.